title: Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
abstract: Based on former animal studies showing the effect of clarithromycin in experimental sepsis by multidrug-resistant Pseudomonas aeruginosa following administration of single doses, the significance of its administration for three consecutive days was evaluated. Acute pyelonephritis was induced in 20 rabbits after inoculation of the test isolate in the renal pelvis. Therapy was administered upon signs of sepsis in group B; A served as control. Survival was recorded; monocytes were isolated for determination of ex vivo TNFalpha secretion. Quantitative cultures of organs were performed after death. Mean survival of groups A and B was 2.65 and 7.95 days respectively. At 24 hours, serum malondialdehyde of group B, which is an index of the oxidant status in serum, was lower than A. Ex vivo release of TNFalpha by the isolated monocytes of group B was lower than A at 3.5 and 48 hours. Tissue bacterial load was similar in two groups after animal death. It is concluded that clarithromycin possessed considerable immunomodulatory effects restraining release of TNFalpha from blood monocytes.
authors.affiliation: 4th Department pf Internal Medicine, University of Athens, Medical School, Greece. giamarel@ath.forthnet.gr
authors.forename: F
authors.initials: F
authors.lastname: Baziaka
authors.forename: E J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
authors.forename: M
authors.initials: M
authors.lastname: Raftogiannis
authors.forename: T
authors.initials: T
authors.lastname: Adamis
authors.forename: V
authors.initials: V
authors.lastname: Tziortzioti
authors.forename: L
authors.initials: L
authors.lastname: Sabracos
authors.forename: M
authors.initials: M
authors.lastname: Chrisofos
authors.forename: P
authors.initials: P
authors.lastname: Koutoukas
authors.forename: H
authors.initials: H
authors.lastname: Giamarellou
authors.forename: E E
authors.initials: EE
authors.lastname: Douzinas
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D011704:Pyelonephritis / Q000382:microbiology; D011817:Rabbits; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D007155:Immunologic Factors; D017291:Clarithromycin